F10 and neoplasm: Consistent with these observations, recent preclinical data demonstrated that myeloid-cell-synthesized FXa impedes anti-tumor immunity in the TME via the activation of PAR2, which in turn directly promotes tumor progression independent of the blood clotting cascade [12,18].